Research Roundup

Debbie Rigby takes a look at the latest in research news Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study In this large multinational study, treatment with SGLT-2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) versus other glucose lowering drugs was associated with a lower risk of

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Forum: Ventolin scheduling
Next Guild launches immunisation course